For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Budget 2023 has nothing in it for women's health
Budget 2023 has nothing in it for women's health
Responding to today’s Budget announcement, Ah-Leen Rayner, chief executive of Breast Cancer Foundation NZ, says: “It’s hard to see how the Government is serious about its women’s health strategy when this Budget has nothing in it for women’s health – let alone breast cancer.
“In this cost of living crisis, the continued refusal to extend the screening age shows the Government expects our older women to continue paying for a life-saving service which should be freely available to them. Extending the breast screening programme to 74 is a solution for the immediate problem of women needlessly dying from breast cancer, yet the Government still won’t see this as a priority.
“With no new money for Pharmac, New Zealand remains at the bottom of the OECD on drug funding. This Budget leaves hundreds of desperate women with incurable breast cancer unable to access medicines that could give them more years to live.”